000			04776nam a22004575i 4500
999			_c128013 _d128013 _x1
001			128013
003			ES-MaUEC
005			20240119142143.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			200916s2020 gw | s |||| 0|eng d
020			_a9783030476823
024	7		_a10.1007/978-3-030-47682-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC271.C5 _b2020 EB
245	0	0	_aPhase I Oncology Drug Development _cedited by Timothy A. Yap, Jordi Rodon, David S. Hong
250			_aFirst edition
264		1	_aCham, Switzerland _bSpringer International Publishing _c2020
300			_a1 recurso en línea (X, 352 páginas) _b47 ilustraciones, 45 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aarchivo de texto _bPDF
490	0		_aMedicine (SpringerNature-11650)
490	0		_aMedicine (R0) (SpringerNature-43714)
505	0		_aParadigm shift in oncology drug development -- Practicalities in setting up phase I trials -- Optimizing the preclinical development of antitumor agents for entry into phase I trials -- Considerations for the development of novel chemotherapies in phase I trials -- Considerations for the development of novel targeted agents in phase I trials -- Development of immunotherapeutic strategies in early phase clinical trials -- Assessment of radiotherapeutic strategies in phase I trials -- Development of combinatorial strategies in phase I trials -- Novel trial designs for early phase clinical trials -- Incorporating pharmacokinetic strategies for phase I trials -- Development of pharmacodynamic biomarkers for phase I trials -- Efficacy considerations for Phase I trials -- Incorporating precision medicine into Phase I clinical trials -- Molecular profiling of patients for clinical trials -- Incorporating circulating biomarkers into clinical trials -- Statistical considerations for early phase clinical trials -- Lessons from hematology for solid tumor drug development. .
520	3		_aThis book provides a detailed review of how oncology drug development has changed over the past decade, and serves as a comprehensive guide for the practicalities in setting up phase I trials. The book covers strategies to accelerate the development of novel antitumor compounds from the laboratory to clinical trials and beyond through the use of innovative mechanism-of-action pharmacodynamic biomarkers and pharmacokinetic studies. The reader will learn about all aspects of modern phase I trial designs, including the incorporation of precision medicine strategies, and approaches for rational patient allocation to novel anticancer therapies. Circulating biomarkers to assess mechanisms of response and resistance are changing the way we are assessing patient selection and are also covered in this book. The development of the different classes of antitumor agents are discussed, including chemotherapy, molecularly targeted agents, immunotherapies and also radiotherapy. The authors also discuss the lessons that the oncology field has learnt from the development of hematology-oncology drugs and how such strategies can be carried over into therapies for solid tumors. There is a dedicated chapter that covers the specialized statistical approaches necessary for phase I trial designs, including novel Bayesian strategies for dose escalation. This volume is designed to help clinicians better understand phase I clinical trials, but would also be of use to translational researchers (MDs and PhDs), and drug developers from academia and industry interested in cancer drug development. It could also be of use to phase I trial study coordinators, oncology nurses and advanced practice providers. Other health professionals interested in the treatment of cancer will also find this book of great value. .
988			_aSpringer_Medicine_2020
650		7	_aAntineoplásicos _xDiseño _2embne _9405304
650		4	_aCáncer _xQuimioterapia _9674463
650		7	_aMedicamentos _2embne _9137892
700	1		_aYap, Timothy A. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aRodon, Jordi _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aHong, David S. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030476816
776	0	8	_iPrinted edition: _z9783030476830
776	0	8	_iPrinted edition: _z9783030476847
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-47682-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_dz _b01/2021 _eo _zSI